Jose Lobo

BRAF mutation predicts sensitivity to MEK inhibition

David B. Solit, Levi A. Garraway, Christine A. Pratilas et al. · Nature · 2005 · 1.3K citations · Full text

Signal Transduction, Braf Mutation, Genetic Disorder +6

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

Qing‐Bai She, David B. Solit, Qing Ye et al. · Cancer Cell · 2005 · 417 citations

Tumor Biology, Signal Transduction, Signaling Pathway +11

RETRACTED: Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling

Qing‐Bai She, Sarat Chandarlapaty, Qing Ye et al. · PLoS ONE · 2008 · 315 citations · Full text

Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel

David B. Solit, Yuhong She, Jose Lobo et al. · Clinical Cancer Research · 2005 · 134 citations · Full text

3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition

David B. Solit, Elmer Santos, Christine A. Pratilas et al. · Cancer Research · 2007 · 64 citations · Full text